EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML

Noor Rashidha Binte Meera Sahib iD, Jameelah Sheik Mohamed, Masturah Bte Mohd Abdul Rashid, Jayalakshmi, Yihao Clement Lin, Yen Lin Chee, Bingwen Eugene Fan, Sanjay De Mel, Melissa Gaik Ming Ooi, Wei-Ying Jen iD, Edward Kai-Hua Chow

Cancer Medicine · 2024

DOI: 10.1002/cam4.70401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Noor Rashidha Binte Meera Sahib und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Science Institute of Singapore, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Precision Medicine. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Science Institute of Singapore Research Centres of Excellence (RCE) Main Grant (NUS Strategic Fund), Baillie Gifford Health Innovation Fund, Singapore lYMPHoma translatiONal studY (SYMPHONY).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite advances made in targeted biomarker‐based therapy for acute myeloid leukemia (AML) treatment, remission is often short and followed by relapse and acquired resistance. Functional precision medicine (FPM) efforts have been shown to improve therapy selection guidance by incorporating comprehensive biological data to tailor individual treatment. However, effectively managing complex biological data, while also ensuring rapid conversion of actionable insights into clinical utility remains challenging.

Methods

We have evaluated the clinical applicability of quadratic phenotypic optimization platform (QPOP), to predict clinical response to combination therapies in AML and reveal patient‐centric insights into combination therapy sensitivities. In this prospective study, 51 primary samples from newly diagnosed (ND) or refractory/relapsed (R/R) AML patients were evaluated by QPOP following ex vivo drug testing.

Results

Individualized drug sensitivity reports were generated in 55/63 (87.3%) patient samples with a median turnaround time of 5 (4–10) days from sample collection to report generation. To evaluate clinical feasibility, QPOP‐predicted response was compared to clinical treatment outcomes and indicated concordant results with 83.3% sensitivity and 90.9% specificity and an overall 86.2% accuracy. Serial QPOP analysis in a FLT3‐mutant patient sample indicated decreased FLT3 inhibitor (FLT3i) sensitivity, which is concordant with increasing FLT3 allelic burden and drug resistance development. Forkhead box M1 (FOXM1)—AKT signaling was subsequently identified to contribute to resistance to FLT3i.

Conclusion

Overall, this study demonstrates the feasibility of applying QPOP as a functional combinatorial precision medicine platform to predict therapeutic sensitivities in AML and provides the basis for prospective clinical trials evaluating ex vivo‐guided combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcutePrecision MedicineHumansMaleFemaleMiddle AgedAgedProspective StudiesAdultAntineoplastic Combined Chemotherapy ProtocolsForkhead Box Protein M1Mutationfms-Like Tyrosine Kinase 3Biomarkers, TumorDrug Resistance, NeoplasmTreatment OutcomeAged, 80 and overYoung Adult

Stichwörter der Autor:innen

AMLFLT3combinatorial drug sensitivityfunctional precision medicine

Substanzen

Forkhead Box Protein M1FOXM1 protein, humanfms-Like Tyrosine Kinase 3Biomarkers, TumorFLT3 protein, human

Autor:innen und Institutionen

  • Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
  • KYAN Technologies Pte Ltd, Singapore.
  • Department of Haematology, Tan Tock Seng Hospital, Singapore.

ORCID-Profile: Noor Rashidha Binte Meera Sahib, Wei-Ying Jen

Förderung

  • Cancer Science Institute of Singapore Research Centres of Excellence (RCE) Main Grant (NUS Strategic Fund)
  • Baillie Gifford Health Innovation Fund
  • Singapore lYMPHoma translatiONal studY (SYMPHONY)
  • Networks of Centres of Excellence of Canada

Zitieren

APA

Sahib, N. R. B. M., Mohamed, J. S., Rashid, M. B. M. A., Jayalakshmi, Lin, Y. C., Chee, Y. L., Fan, B. E., De Mel, S., Ooi, M. G. M., Jen, W. Y., & Chow, E. K. (2024). A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer Medicine. https://doi.org/10.1002/cam4.70401

Vancouver

Sahib NRBM, Mohamed JS, Rashid MBMA, Jayalakshmi, Lin YC, Chee YL, et al. A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer Medicine. 2024. doi:10.1002/cam4.70401

BibTeX
@article{Sahib2024,
  author = {Sahib, Noor Rashidha Binte Meera and Mohamed, Jameelah Sheik and Rashid, Masturah Bte Mohd Abdul and Jayalakshmi and Lin, Yihao Clement and Chee, Yen Lin and Fan, Bingwen Eugene and De Mel, Sanjay and Ooi, Melissa Gaik Ming and Jen, Wei-Ying and Chow, Edward Kai-Hua},
  title = {A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70401}
}
Kostenlos starten →